Personalized treatment for Andersen-Tawil syndrome and MEPPC
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This study tests whether a personalized approach to treating Andersen-Tawil syndrome (ATS) and a related heart condition called MEPPC can reduce dangerous heart rhythms. It uses a type of medication called flecainide, which you may already be taking, to see if it works better in a tailored way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Andersen-Tawil syndrome (ATS) or MEPPC, and for MEPPC you must have a specific genetic change.
- You have had irregular heart rhythms (ventricular arrhythmias) at some point, as seen on a heart monitor.
- You are currently taking flecainide.
- You are 18 years or older.
- You are not pregnant and do not have other significant heart conditions or other heart rhythm disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the medication flecainide can reduce frequent extra heartbeats (called PVCs) that come from normal heart tissue, and may help prevent or reverse heart muscle problems caused by these extra beats.
This trial tests a new drug called AGP100 for people with CPVT, a genetic heart condition that causes dangerous heartbeats during exercise. The goal is to see if AGP100 can safely reduce these abnormal heart rhythms.
This study looks at how personalized voltage maps of the heart's upper left chamber can help doctors better understand and treat persistent atrial fibrillation (an irregular heartbeat). It aims to improve the success of a procedure called catheter ablation.
This study looks at how a person’s genetics may affect how well and safely antiarrhythmic medicines work for atrial fibrillation (AF). If you join, you may get medicine options like flecainide or sotalol, and researchers compare outcomes to genetic information.
This study looks at the risk of a fast heart rhythm (ventricular tachycardia) in people with genetic heart muscle diseases. It tests whether having a specific genetic change affects the success of a heart ablation procedure.
This trial studies whether a device-based fast pacing therapy (called ATP) can better treat certain rapid heart rhythm problems in people born with a heart condition. It may help prevent or reduce episodes of atrial (upper-chamber) arrhythmias that occur despite having a pacing/defibrillator device.
Hear when a new Andersen Tawil Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.